TX-KAHUNA-WORKFORCE
29.11.2023 17:09:26 CET | Business Wire | Press release
Kahuna Workforce Solutions, the leading provider of operational skills and competency management software, today announced a $21 million Series B funding round led by Resolve Growth Partners. This investment marks a significant milestone in Kahuna’s growth journey and solidifies the criticality of skills management for industries with technical frontline workforces.
As organizations navigate an ever-evolving and complex landscape, understanding, validating, and aligning workforce skills to strategic business objectives is central to operating at the highest level. Kahuna is at the forefront of skills management technology, equipping organizations with actionable skill insights for effective assessment, training and development, and staffing and deployment initiatives, ultimately enabling resilient operations, improved productivity, and a more competitive workforce.
Kahuna’s customer base of leading Fortune 500 energy, manufacturing, and field service organizations, and world-renowned healthcare systems, is a testament to the platform’s scalability and robustness in meeting the rigorous demands of complex operational needs. The flagship skills management platform digitizes granular skills data, removing the burden that often comes with tracking skills manually in Excel spreadsheets or a traditional HRIS. Organizations can dynamically track skills, identify and analyze skills gaps, and provide targeted development opportunities whether at the bedside, in the field, or on the plant floor.
Kahuna plans to use the growth funding strategically to accelerate and enhance product development and innovation; expand its team by adding key roles across sales and marketing, product development, customer success, and engineering; and increase operational capabilities to continue supporting global customers as they adopt skills-based strategies to achieve operational excellence.
“We are thrilled to work with Resolve as Kahuna begins the next growth phase. Their expertise in enterprise software, and commitment to innovation and continuous improvement fully aligns with our mission, vision, and goals for Kahuna,” said Jai Shah, CEO of Kahuna Workforce Solutions. “This funding fuels our ability to provide mission-critical skills management solutions and support as we revolutionize how organizations manage and optimize workforce skills and capabilities.”
“Kahuna stands out as a category leader, as demonstrated by the quality of logos in their portfolio. They offer best-in-class skills management software and create true partnerships with customers to achieve transformative business value and operational outcomes,” said Jit Sinha, Co-Founder and Partner at Resolve Growth Partners. “Kahuna’s extensive understanding of market needs positions them uniquely in this space. Our investment is a testament to the confidence we have in Kahuna to continue leading and offering unparalleled solutions to meet the evolving needs of customers globally.”
With Resolve’s partnership, this round of funding positions Kahuna to expand its impact, empowering organizations to build resilient, future-ready workforces with operational skilling tools and initiatives for frontline workers.
About Resolve Growth Partners
Resolve Growth Partners is a growth equity firm focused on investing in B2B software companies and enabling passionate, committed entrepreneurs to accelerate growth. Resolve provides expertise and repeatable best practices across talent, go-to-market, and operations. For more information on Resolve, visit http://www.resolvegrowth.com.
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129383752/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom